Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-in-class drugs, like NKP-1339, can take us one step further to address this high unmet need." While Dr. Burris commented, "The results to date indicate that NKP-1339 could be a promising new agent that would enhance our anti-cancer armamentarium."

About Niiki Pharma

Niiki Pharma Inc. is an oncology therapeutics development company with a pipeline of novel targeted anti-cancer agents. For more information, visit www.niikipharma.com.

About Translational Genomics Institute

The Translational Genomics Research Institute (TGen) is dedicated to conducting groundbreaking research with diseases such as cancer, neurological disorders and diabetes. For more information, visit www.tgen.org

About Sarah Canon Research Institute

Sarah Cannon Research Institute (SCRI) is a global clinical research organization focusing on advancing therapies and accelerating drug development in areas such as oncology, cardiology and gastroenterology. For more information, visit http://sarahcannonresearch.com.


'/>"/>
SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... YORK , Jan. 17, 2017 EU5 ... GlobalData,s new report, "EU5 Glucose Monitoring Market Outlook ... Glucose Monitoring market. The report provides value, in millions ... (USD) within market segments - Blood Glucose Meters, Blood ... provides company shares and distribution shares data for each ...
(Date:1/17/2017)... 17, 2017 Paragon Bioservices received a multiple-award, ... services for a variety of National Institute ... product development activities. The IDIQ mechanism will allow ... task order awards up to $159 million. ... and process development of biopharmaceuticals, is one of ...
(Date:1/17/2017)... Pa. , Jan. 17, 2017  Pennsylvania ... today announced applications for medical marijuana growers/processors and ... Medical Marijuana Program website . Permit applications will ... 2017. "This is an important step ... who desperately need it," Secretary Murphy said. "We,ve ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... ... that their Vice President of Franchise Development, Paula Turner Pizarro, was recently featured ... program, which features the insights of top business leaders from across the globe, ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment to quality ... achieved certification to ISO 13485. This certification is another way they are making constant ... and services that they need. , The ISO 13485 Certification is a major accomplishment ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy ... for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael ... field of biosimilars through thought leader interaction in, live video and interactive digital ...
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, ... to enamel erosion, and those dental problems can increase the risk of pregnancy ... pregnant women are failing to get the dental care they need. Agoura Hills ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, ... each patient. Dentists have several general anesthesia alternatives and finding the right option can ... Dental College in Tokyo, Japan wanted to find out which anesthetic was the better ...
Breaking Medicine News(10 mins):